Lyell Immunopharma/$LYEL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lyell Immunopharma
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
- Ticker
- $LYEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 161
- Headquarters
- South San Francisco, United States
- Website
- www.lyell.com
LYEL Metrics
BasicAdvanced
$267M
-
-$11.82
-0.07
-
Price and volume
Market cap
$267M
Beta
-0.07
52-week high
$45.00
52-week low
$7.20
Average daily volume
156K
Financial strength
Current ratio
5.356
Quick ratio
5.12
Long term debt to equity
0.158
Total debt to equity
0.199
Profitability
EBITDA (TTM)
-180.944
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-920,285.19%
Operating margin (TTM)
-705,411.11%
Management effectiveness
Return on assets (TTM)
-34.18%
Return on equity (TTM)
-93.28%
Valuation
Price to revenue (TTM)
8,473.52
Price to book
1.09
Price to tangible book (TTM)
1.09
Price to free cash flow (TTM)
-1.707
Free cash flow yield (TTM)
-58.59%
Free cash flow per share (TTM)
-6.374
Growth
Revenue change (TTM)
-55.00%
Earnings per share change (TTM)
-49.73%
3-year revenue growth (CAGR)
-91.78%
3-year earnings per share growth (CAGR)
-11.05%
What the Analysts think about LYEL
Analyst ratings (Buy, Hold, Sell) for Lyell Immunopharma stock.
Analyst projections of the future price of Lyell Immunopharma stock.
LYEL Financial Performance
Revenues and expenses
LYEL Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing LYEL
Fund name | Fund size | $LYEL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Ageing Population$AGED | $953M | 0.01% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.01% |
iShares Ageing Population£AGES | $953M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.